NeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis

Reuters12-08

<a href="https://laohu8.com/S/NEO">NeoGenomics</a> Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis

NeoGenomics Inc. has announced that it will present new data from a real-world study on comprehensive genomic profiling (CGP) in myeloid malignancies at the 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The study evaluates the Neo Comprehensive Myeloid panel, a next-generation sequencing assay designed to provide a comprehensive assessment of genomic changes in myeloid cancers. The poster, titled "Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis," will be presented on December 8. The data highlights the ability of the CGP panel to detect important genomic variants, supporting diagnosis, prognosis, and therapy selection for acute myeloid leukemia, myelodysplastic neoplasms, and myeloproliferative neoplasms. Results of the study will be presented at the upcoming conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208548164) on December 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589353678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589353678","market":"fut","top_or_hot":-1,"title":"NeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics Inc. has announced that it will present new data from a real-world study on comprehensive genomic profiling (CGP) in myeloid malignancies at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The study evaluates the Neo Comprehensive Myeloid panel, a next-generation sequencing assay designed to provide a comprehensive assessment of genomic changes in myeloid cancers. The poster, titled \"Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\" will be presented on December 8. The data highlights the ability of the CGP panel to detect important genomic variants, supporting diagnosis, prognosis, and therapy selection for acute myeloid leukemia, myelodysplastic neoplasms, and myeloproliferative neoplasms. Results of the study will be presented at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208548164) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics Inc. has announced that it will present new data from a real-world study on comprehensive genomic profiling (CGP) in myeloid malignancies at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The study evaluates the Neo Comprehensive Myeloid panel, a next-generation sequencing assay designed to provide a comprehensive assessment of genomic changes in myeloid cancers. The poster, titled \"Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\" will be presented on December 8. The data highlights the ability of the CGP panel to detect important genomic variants, supporting diagnosis, prognosis, and therapy selection for acute myeloid leukemia, myelodysplastic neoplasms, and myeloproliferative neoplasms. Results of the study will be presented at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208548164) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLbS6NtM:1","article_id":"2589353678","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589353678","pubTimestamp":1765199122,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeoGenomics Inc. has announced that it will present new data from a real-world study on comprehensive genomic profiling  in myeloid malignancies at the 67th American Society of Hematology  Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The study evaluates the Neo Comprehensive Myeloid panel, a next-generation sequencing assay designed to provide a comprehensive assessment of genomic changes in myeloid cancers. The poster, titled \"Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\" will be presented on December 8. The data highlights the ability of the CGP panel to detect important genomic variants, supporting diagnosis, prognosis, and therapy selection for acute myeloid leukemia, myelodysplastic neoplasms, and myeloproliferative neoplasms. Results of the study will be presented at the upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","NEO":"NeoGenomics","BK4121":"生命科学工具和服务"},"translate_title":"NeoGenomics公布的研究显示先进的基因组图谱可改善骨髓癌诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":0.9},"content_text":"NeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis\n    \n\n        NeoGenomics Inc. has announced that it will present new data from a real-world study on comprehensive genomic profiling (CGP) in myeloid malignancies at the 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The study evaluates the Neo Comprehensive Myeloid panel, a next-generation sequencing assay designed to provide a comprehensive assessment of genomic changes in myeloid cancers. The poster, titled \"Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\" will be presented on December 8. The data highlights the ability of the CGP panel to detect important genomic variants, supporting diagnosis, prognosis, and therapy selection for acute myeloid leukemia, myelodysplastic neoplasms, and myeloproliferative neoplasms. Results of the study will be presented at the upcoming conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208548164) on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589353678","isCrawlerRequest":true}